| Literature DB >> 28864780 |
Xiaolin Wu1, Xipeng Chen1, Wenxiang Mi1, Tingting Wu1, Qinhua Gu1, Hui Huang2.
Abstract
Peri-implantitis, which is characterized by dense inflammatory infiltrates and increased osteoclast activity, can lead to alveolar bone destruction and implantation failure. miRNAs participate in the regulation of various inflammatory diseases, such as periodontitis and osteoporosis. Therefore, the present study aimed to investigate the differential expression of miRNAs in canine peri-implantitis and to explore the functions of their target genes. An miRNA sequence analysis was used to identify differentially expressed miRNAs in peri-implantitis. Under the criteria of a fold-change >1.5 and P<0.01, 8 up-regulated and 30 down-regulated miRNAs were selected for predictions of target genes and their biological functions. Based on the results of Gene Ontology (GO) and KEGG pathway analyses, these miRNAs may fine-tune the inflammatory process in peri-implantitis through an intricate mechanism. The results of quantitative real-time PCR (qRT-PCR) revealed that let-7g, miR-27a, and miR-145 may play important roles in peri-implantitis and are worth further investigation. The results of the present study provide insights into the potential biological effects of the differentially expressed miRNAs, and specific enrichment of target genes involved in the mitogen-activated protein kinase (MAPK) signaling pathway was observed. These findings highlight the intricate and specific roles of miRNAs in inflammation and osteoclastogenesis, both of which are key aspects of peri-implantitis, and thus may contribute to future investigations of the etiology, underlying mechanism, and treatment of peri-implantitis.Entities:
Keywords: miRNA sequence analysis; microRNA; osteoclasts; peri-implantitis
Mesh:
Substances:
Year: 2017 PMID: 28864780 PMCID: PMC5964874 DOI: 10.1042/BSR20170768
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Experimental peri-implantitis
(A) Outline of the animal experiment. (B) Clinical photographs: (a) implant installment; (b) 2 months after ligament placement. (C) Representative X-ray image of the implant before and after ligature placement. (D) Clinical parameters examined 2 months after the induction of inflammation, * represents P<0.05.
List of the top differentially expressed miRNAs between diseased and healthy gingival tissues (P<0.01)
| miRNAs | Mature sequence | Fold-change | Regulation |
|---|---|---|---|
| (A) Top eight miRNAs with increased expression in diseased compared with healthy gingiva | |||
| cfa- | AACUGUUUGCAGAGGAAACUGA | 2.52 | Up |
| cfa- | UUUGUUCGUUCGGCUCGCGUGA | 2.43 | Up |
| cfa- | UGAGGUAGUAAGUUGUAUUGUU | 2.38 | Up |
| cfa- | GUCCAGUUUUCCCAGGAAUCCCU | 1.96 | Up |
| cfa-let-7e | UGAGGUAGGAGGUUGUAUAGUU | 1.71 | Up |
| cfa- | CCCAUAAAGUAGAAAGCACUA | 1.71 | Up |
| cfa- | AUGCACCUGGGCAAGGAUUCU | 1.70 | Up |
| cfa- | UGGAAGACUAGUGAUUUUGUUGU | 1.68 | Up |
| (B) Top 30 miRNAs with decreased expression in diseased compared with healthy gingiva | |||
| cfa-let-7g | UGAGGUAGUAGUUUGUACAGUU | −1.51 | Down |
| cfa- | UCCUGUACUGAGCUGCCCCGA | −1.51 | Down |
| cfa- | UCAGUGCAUGACAGAACUUGG | −1.51 | Down |
| cfa- | UCGGAUCCGUCUGAGCUUGGCU | −1.55 | Down |
| cfa- | CUUGGCACCUAGUAAGCACU | −1.56 | Down |
| cfa- | UACAGUACUGUGAUAACUGA | −1.57 | Down |
| cfa- | UAGCAGCACGUAAAUAUUGGCG | −1.61 | Down |
| cfa- | CAUCUUACCGGACAGUGCUGGA | −1.61 | Down |
| cfa- | ACCACAGGGUAGAACCACGGA | −1.67 | Down |
| cfa- | UUCACAGUGGCUAAGUUCUGC | −1.69 | Down |
| cfa- | UGAGAACUGAAUUCCAUGGGUU | −1.74 | Down |
| cfa- | UUCCCUUUGUCAUCCUAUGCCU | −1.80 | Down |
| cfa- | UAGCACCAUCUGAAAUCGGUUA | −1.81 | Down |
| cfa- | UUCAAGUAAUCCAGGAUAGGCU | −1.83 | Down |
| cfa- | AAACCGUUACCAUUACUGAGUU | −1.89 | Down |
| cfa- | UCCCUGAGACCCUUUAACCUGU | −1.92 | Down |
| cfa- | CAAAGUGCUGUUCGUGCAGGUAG | −1.96 | Down |
| cfa- | UUAUCAGAAUCUCCAGGGGUAC | −1.97 | Down |
| cfa- | UUCACAGUGGCUAAGUUCCG | −2.03 | Down |
| cfa- | CAUGCCUUGAGUGUAGGACCGU | −2.09 | Down |
| cfa-let-7c | UGAGGUAGUAGGUUGUAUGGUU | −2.11 | Down |
| cfa- | AUCACAUUGCCAGGGAUUU | −2.33 | Down |
| cfa- | UUCCCUUUGUCAUCCUUUGCCU | −2.35 | Down |
| cfa- | UAUUGCACUCGUCCCGGCCUCC | −2.40 | Down |
| cfa- | UCUCACACAGAAAUCGCACCCGU | −2.58 | Down |
| cfa- | UUAUAAAGCAAUGAGACUGAUU | −3.04 | Down |
| cfa- | UUAUAAUACAACCUGAUAAGU | −3.09 | Down |
| cfa- | UCUUUGGUUAUCUAGCUGUAUGA | −4.22 | Down |
| cfa- | UAAUACUGUCUGGUAAUGCCGU | −5.58 | Down |
| cfa- | UAAAGUGCUUAUAGUGCAGGUAG | −7.52 | Down |
Figure 2Validation of sequencing data by qRT-PCR
Fold-changes in the expression of three down-regulated miRNAs (let-7g, miR-27a, and miR-29a) and two up-regulated miRNAs (miR-142 and miR-145) were verified. *, statistically significant difference between the peri-implantitis and control groups, P<0.05.
Figure 3Functional annotations of target genes
Biological process categories of target genes of low-abundance miRNAs (A) and high-abundance miRNAs (B) in the GO analysis. The numbers shown in each section of the pie chart represent the number of putative target genes mapped to the corresponding GO terms. Bar graphs show the −log10 (P-value) of each GO term.
Enriched KEGG pathways involving target genes of 30 low-abundance miRNAs (P<0.05)
| Pathway ID | Definition | Hits | Total | Percent (%) | Fisher-P value |
|---|---|---|---|---|---|
| cfa05206 | MiRNAs in cancer | 31 | 139 | 22.30% | 2.70E-05 |
| cfa05200 | Pathways in cancer | 62 | 393 | 15.78% | 4.29E-04 |
| cfa04010 | MAPK signaling pathway | 43 | 252 | 17.06% | 6.55E-04 |
| cfa04060 | Cytokine–cytokine receptor interaction | 38 | 216 | 17.59% | 7.35E-04 |
| cfa04151 | PI3K-Akt signaling pathway | 53 | 334 | 15.87% | 9.73E-04 |
| cfa03060 | Protein export | 8 | 23 | 34.78% | 1.55E-03 |
| cfa04933 | AGE-RAGE signaling pathway in diabetic complications | 21 | 102 | 20.59% | 1.57E-03 |
| cfa04510 | Focal adhesion | 35 | 204 | 17.16% | 1.84E-03 |
| cfa04810 | Regulation of actin cytoskeleton | 36 | 212 | 16.98% | 1.92E-03 |
| cfa04974 | Protein digestion and absorption | 18 | 84 | 21.43% | 2.08E-03 |
| cfa04062 | Chemokine signaling pathway | 30 | 172 | 17.44% | 2.94E-03 |
| cfa04722 | Neurotrophin signaling pathway | 22 | 120 | 18.33% | 5.56E-03 |
| cfa04320 | Dorsoventral axis formation | 8 | 28 | 28.57% | 6.14E-03 |
| cfa05205 | Proteoglycans in cancer | 32 | 197 | 16.24% | 6.65E-03 |
| cfa04666 | Fc γ R-mediated phagocytosis | 17 | 88 | 19.32% | 8.25E-03 |
| cfa04068 | FoxO signaling pathway | 23 | 132 | 17.42% | 8.72E-03 |
| cfa04668 | TNF signaling pathway | 19 | 105 | 18.10% | 1.10E-02 |
| cfa04670 | Leukocyte transendothelial migration | 21 | 120 | 17.50% | 1.13E-02 |
| cfa04360 | Axon guidance | 22 | 128 | 17.19% | 1.19E-02 |
| cfa04550 | Signaling pathways regulating pluripotency of stem cells | 23 | 138 | 16.67% | 1.47E-02 |
| cfa05212 | Pancreatic cancer | 13 | 65 | 20.00% | 1.48E-02 |
| cfa00310 | Lysine degradation | 11 | 52 | 21.15% | 1.60E-02 |
| cfa04115 | p53 signaling pathway | 13 | 66 | 19.70% | 1.67E-02 |
| cfa04350 | TGF-β signaling pathway | 15 | 82 | 18.29% | 2.04E-02 |
| cfa04512 | ECM–receptor interaction | 15 | 82 | 18.29% | 2.04E-02 |
| cfa05222 | Small cell lung cancer | 15 | 84 | 17.86% | 2.50E-02 |
| cfa04919 | Thyroid hormone signaling pathway | 19 | 115 | 16.52% | 2.72E-02 |
| cfa02010 | ABC transporters | 9 | 43 | 20.93% | 2.99E-02 |
| cfa05166 | HTLV-I infection | 35 | 246 | 14.23% | 3.26E-02 |
| cfa04064 | NF-κB signaling pathway | 15 | 87 | 17.24% | 3.32E-02 |
| cfa05202 | Transcriptional misregulation in cancer | 24 | 158 | 15.19% | 3.59E-02 |
| cfa05220 | Chronic myeloid leukemia | 13 | 73 | 17.81% | 3.61E-02 |
| cfa05146 | Amoebiasis | 16 | 96 | 16.67% | 3.77E-02 |
| cfa04917 | Prolactin signaling pathway | 13 | 74 | 17.57% | 3.98E-02 |
| cfa04144 | Endocytosis | 35 | 252 | 13.89% | 4.42E-02 |
| cfa04620 | Toll-like receptor signaling pathway | 16 | 98 | 16.33% | 4.44E-02 |
| cfa04014 | Ras signaling pathway | 31 | 220 | 14.09% | 4.74E-02 |
| cfa00603 | Glycosphingolipid biosynthesis – globo series | 4 | 14 | 28.57% | 4.96E-02 |
Enriched KEGG pathways involving target genes of eight high-abundance miRNAs (P<0.05)
| Pathway ID | Definition | Hits | Total | Percent (%) | Fisher-P value |
|---|---|---|---|---|---|
| cfa04145 | Phagosome | 11 | 141 | 7.80% | 3.07E-03 |
| cfa04520 | Adherens junction | 7 | 73 | 9.59% | 5.73E-03 |
| cfa04919 | Thyroid hormone signaling pathway | 9 | 115 | 7.83% | 7.04E-03 |
| cfa04142 | Lysosome | 9 | 117 | 7.69% | 7.86E-03 |
| cfa04320 | Dorsoventral axis formation | 4 | 28 | 14.29% | 8.87E-03 |
| cfa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 6 | 72 | 8.33% | 1.97E-02 |
| cfa05152 | Tuberculosis | 10 | 164 | 6.10% | 2.40E-02 |
| cfa04916 | Melanogenesis | 7 | 100 | 7.00% | 2.89E-02 |
| cfa05323 | Rheumatoid arthritis | 6 | 82 | 7.32% | 3.47E-02 |
| cfa04390 | Hippo signaling pathway | 9 | 153 | 5.88% | 3.83E-02 |
| cfa05414 | Dilated cardiomyopathy | 6 | 85 | 7.06% | 4.03E-02 |
| cfa00130 | Ubiquinone and other terpenoid-quinone biosynthesis | 2 | 11 | 18.18% | 4.05E-02 |
| cfa03420 | Nucleotide excision repair | 4 | 44 | 9.09% | 4.08E-02 |
Figure 4The KEGG analysis annotated the MAPK signaling pathway as significantly enriched in peri-implantitis
Yellow nodes represent up-regulated genes enriched in peri-implantitis.